Median overall survival (OS)
(95% CI 12.1-25.8) across all patients treated with NovoTTF-100L and pemetrexed + cisplatin/carboplatin
Median progression-free survival (PFS)
(95% CI 6.7-8.6) across all patients treated with NovoTTF-100L and pemetrexed + cisplatin/carboplatin
The overwhelming majority of patients treated with NovoTTF-100L and pemetrexed + cisplatin/carboplatin (97%) experienced a measurable disease control rate (n=72)*,†
NovoTTF-100L is FDA-approved as 1st-line therapy for patients with MPM1,2
*In patients with at least one follow-up CT scan performed.
†Minimum follow-up of 12 months.
References: 1. NovoTTF-100L Instructions For Use for Unresectable Malignant Pleural Mesothelioma. Novocure 2019. 2. FDA Approves the NovoTTF-100L™ System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma [press release]. St. Helier, Jersey: Business Wire; May 23, 2019.